Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome

RA patients with MetS showed an increased CVD risk profile based on both a higher prevalence of CVD risk factors and structural vascular changes. A treat-to-target approach of CVD risk factors reduced cIMT progression only in RA patients without MetS.